Head to Head Review: Hyperion DeFi (HYPD) versus Its Rivals

Hyperion DeFi (NASDAQ:HYPD) is one of 421 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Hyperion DeFi to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Hyperion DeFi and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hyperion DeFi	$60,000.00	-$49.82 million	-0.27
Hyperion DeFi Competitors	$155.98 million	-$11.44 million	-57.85

Hyperion DeFi’s competitors have higher revenue and earnings than Hyperion DeFi. Hyperion DeFi is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Hyperion DeFi and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	0	4	0	0	2.00
Hyperion DeFi Competitors	857	2223	4747	57	2.51

Hyperion DeFi presently has a consensus target price of $2.00, suggesting a potential downside of 87.39%. As a group, “Biotechnology” companies have a potential upside of 39.76%. Given Hyperion DeFi’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Hyperion DeFi has less favorable growth aspects than its competitors.

Risk & Volatility

Hyperion DeFi has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500. Comparatively, Hyperion DeFi’s competitors have a beta of 1.37, suggesting that their average stock price is 37% more volatile than the S&P 500.

Profitability

This table compares Hyperion DeFi and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	-62,238.41%	N/A	-316.90%
Hyperion DeFi Competitors	-14,816.17%	40.80%	-32.07%

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 29.5% of shares of all “Biotechnology” companies are owned by institutional investors. 7.1% of Hyperion DeFi shares are owned by company insiders. Comparatively, 22.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Hyperion DeFi competitors beat Hyperion DeFi on 11 of the 13 factors compared.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.